Drug-related AEs during deferasirox treatment. Annual frequency of the most common (≥ 5% overall) investigator-assessed drug-related AEs during deferasirox treatment in the (A) deferasirox and (B) crossover cohorts. *Reports of abdominal pain and abdominal pain (top) are combined and presented as abdominal pain